Wenda Pharmaceutical Technology

Company Drug

Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma

Fineline Cube May 9, 2026

Zhejiang Wenda Pharmaceutical Technology Co., Ltd. announced it has received Breakthrough Therapy Designation (BTD) from...

Company Drug

Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma

Company Drug

European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance

Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Company Drug

Keymed Biosciences Secures NMPA Breakthrough Therapy Designation for CM336 in AL Amyloidosis